Medical translation is not general translation with harder vocabulary. It is a specialisation with its own failure modes, where a single wrong term can compromise patient safety, invalidate a regulatory submission, or create legal exposure for the organisation that commissioned the work. Companies and professionals evaluating translation providers for medical documentation need to understand where the risks sit and what separates an adequate service from an insufficient one.
Why medical terminology is difficult to translate
Medical language operates on three distinct layers that often coexist in the same document: international anatomical nomenclature, everyday clinical vocabulary, and regulatory pharmaceutical language. Each layer follows different conventions and demands different competencies.
Anatomical nomenclature follows the Terminologia Anatomica 2 (TA2), published by the Federative International Programme for Anatomical Terminology. Terms are Latin or Latin-derived, with defined equivalents in each language. The difficulty arises when a single bone, muscle, or structure has a classical name, a common clinical name, and an abbreviation in active use, and the source text moves freely between all three. The translator must recognise each register and be consistent in the equivalent chosen.
Clinical vocabulary is less stable. It includes eponyms (Crohn's disease, the Babinski reflex), locally variable acronyms, and specialty-specific terminology that has no direct equivalent in other languages. A cardiologist uses terms a neurologist would recognise but not reach for instinctively. A generalist translator who accepts any medical text without declared subspecialty expertise is a genuine risk.
Regulatory pharmaceutical language is the most codified of the three. Terms such as *excipient*, *active substance*, *bioequivalence*, *pharmacokinetics*, and *adverse reaction* have precise definitions in EMA and FDA regulations. Any deviation from official terminology creates inconsistencies in submission dossiers. In pharmaceutical translation, terminological compliance is not a quality preference: it is a condition for regulatory acceptance.
Common document types and their specific requirements
Medical documentation requiring translation is varied, and each type carries distinct terminological obligations.
Summaries of Product Characteristics (SmPC) and package leaflets are the most regulated documents in pharmaceutical translation. Adverse reaction terminology must align with MedDRA (Medical Dictionary for Regulatory Activities), and substance names must follow the European Pharmacopoeia. Any divergence from EMA-approved language is flagged during regulatory review.
Clinical trial protocols require absolute consistency across language versions. Inclusion and exclusion criteria, primary and secondary endpoints, and data collection procedures must be translated with the same precision with which they were drafted. An ambiguity in the translated protocol can affect the quality of data collected across participating sites.
Medical device instructions for use (IFU) and user manuals carry specific obligations under Regulation (EU) 2017/745 (MDR). Medical device technical documentation must include instructions for use in the official language of each Member State where the product is placed on the market, with terminology that is verifiable and traceable.
Clinical study reports and scientific publications have different requirements. The register is academic, terminology follows international publication conventions (MeSH, for instance), and readability for the specialist audience takes priority over accessibility for a general reader.
What to evaluate in a medical translation provider
Assessing a provider in this field goes well beyond checking whether their translators hold a degree in health sciences. The criteria that matter are more granular.
Declared subspecialty. Medicine is not a homogeneous domain. A translator competent in cardiology may not have sufficient familiarity with molecular oncology or paediatric neurology. It is worth verifying that the provider can assign specialists in the specific subspecialty relevant to the project.
Terminology management. For high-volume projects or documents that form part of a larger submission, the availability of controlled glossaries and client-specific translation memories is critical. Without these tools, consistency between the SmPC, the protocol, and the clinical report cannot be guaranteed.
Independent review. In medical documentation, self-review by the translator is not sufficient. A process that includes an independent reviewer with expertise in the same subspecialty is the minimum acceptable standard for documentation with regulatory or clinical impact.
Certification and traceability. ISO 17100:2015 certification guarantees that the translation process meets defined requirements for the qualification of human resources and quality control. For documentation subject to regulatory audit, this traceability may be required by the authority itself.
Experience with specific regulatory bodies. Submissions to the EMA, MHRA, ANVISA, or FDA carry distinct requirements. A provider with experience in regulatory submissions will be familiar with the relevant templates, terminological conventions, and the most common errors that generate requests for clarification.
How M21Global approaches medical and pharmaceutical translation
M21Global has worked with medical and pharmaceutical documentation for over 20 years, with translators specialised by clinical subspecialty and access to updated terminological glossaries. The Estratégica service tier applies a three-linguist workflow — translator, reviewer, and quality reviewer — certified ISO 17100:2015 by Bureau Veritas, and is suited to regulatory documentation, submission dossiers, and any content where a terminological error carries clinical or legal consequences. For large volumes of internal reference documentation, the IAH+ service combines machine translation with selective human review, reducing turnaround times without compromising terminological traceability. Organisations evaluating providers for medical or pharmaceutical documentation are welcome to contact M21Global for a project analysis: the team will identify the appropriate service level for the document type and regulatory context before any commitment is made.
Related Services
Request a free medical translation quote
- Request a free medical translation quote
- Medical Device Documentation Translation Mdr Compliance
- Translating Clinical Trial Protocols Regulatory Submission
- Drug Labeling Translation
Frequently Asked Questions
What is the difference between medical translation and pharmaceutical translation?
Medical translation covers all clinical and scientific documentation, including reports, protocols, and publications. Pharmaceutical translation focuses specifically on regulatory documentation for medicines, such as SmPCs, package leaflets, and submission dossiers for the EMA or other authorities. The two areas share terminology but carry distinct regulatory requirements.
Is ISO 17100 certification required for medical document translation?
It is not always legally mandatory, but it is frequently required or strongly recommended for documentation subject to regulatory audit, such as EMA submission dossiers or MDR technical files. The certification provides traceability of the translation process and verifiable qualification of the translators involved.
What is MedDRA and why does it matter in medical translation?
MedDRA (Medical Dictionary for Regulatory Activities) is the international terminological dictionary used by regulatory authorities to classify adverse reactions and medical conditions. In the translation of SmPCs and safety reports, adverse reaction terminology must align with MedDRA entries to ensure documents are accepted by the relevant authority.
How can terminological consistency be maintained across multiple related medical documents?
Consistency is maintained through controlled glossaries and project-specific or client-specific translation memories. A provider that does not use these tools cannot guarantee that the same term is rendered identically across the SmPC, the protocol, and the clinical report.
What factors affect the cost of medical translation?
The main factors are document volume, language pair, subject complexity, the level of review required, urgency, and whether regulatory certification is needed. Medical translation with full ISO 17100-compliant review costs more than standard translation because it involves multiple qualified specialists and a documented quality process.
